Core Insights - Klotho Neurosciences, Inc. is advancing the manufacturing and process development for KLTO-202, a gene therapy aimed at treating amyotrophic lateral sclerosis (ALS) [1] - The company has licensed a unique RNA splice variant of the alpha-Klotho gene from the Autonomous University of Barcelona, which is crucial for developing gene therapies [2] - Animal studies have shown that amplifying the levels of secreted alpha-Klotho (s-KL) through gene therapy leads to favorable therapeutic outcomes in models of ALS and other neurodegenerative diseases [2] - The company anticipates an eight-month timeline to complete process development and manufacturing, followed by four to six months for FDA-related activities, aiming to start clinical trials in ALS patients by Q3 of the following year [3] - The CEO highlighted a more efficient method for producing the AAV vector to deliver the s-KL gene directly to motor neurons, which are significantly affected by ALS [4] Company Overview - Klotho Neurosciences, Inc. focuses on innovative cell and gene therapies derived from the human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [5] - The company's portfolio includes proprietary cell and gene therapy programs utilizing DNA and RNA therapeutics, along with genomics-based diagnostic assays [5] - The management team consists of experienced individuals in biopharmaceutical product development and commercialization [5]
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS